

Bilirubin Ameliorate Kidney Fibrosis Through Regulation of Hypoxia-inducible Factor Pathway

Do Hyoung Kim¹, Seung Hee Yang², Jin Ho Hwang³, Jin Hyuk Kim²
Jin Ho Paik⁴, Dong Ki Kim⁵, Ho Jun Chin⁶, Yoon Kyu Oh³
Chun Soo Lim³, Yon Su Kim⁵, Jung Pyo Lee³

Department of Internal Medicine¹ Chung-Ang University College of Medicine
Seoul National University Kidney Research Institute²

Department of Internal Medicine³ Seoul National University Boramae Medical Center

Department of Pathology⁴ Seoul National University Bundang Hospital

Department of Internal Medicine⁵ Seoul National University College of Medicine

Department of Internal Medicine⁶ Seoul National University Bundang Hospital

Purpose: Bilirubin is a protective factor with antioxidant and anti-inflammatory properties to inhibit the scavenge oxygen radicals, and counteract oxidative stress. Here, we evaluated that direct administration of bilirubin could attenuate kidney fibrosis.

Methods: Bilirubin was daily pretreated by intraperitoneal administration for a week (30 mg/kg/day). Unilateral ureteral obstruction (UUO) was used as a model of kidney fibrosis in C57BL/6 mice. Bilirubin was persistently treated with same dose for a week more. We analyzed the histological findings and mRNA expression in a 7-day UUO mouse.

Results: Serum bilirubin level significantly increased in bilirubin-treated group compared with vehicle-treated group (0.62±0.08 vs. 0.11±0.01 mg/dl, p<0.01). Bilirubin-treatment significantly improved tubulointerstitial fibrosis and infiltration of inflammatory cells. Fibroblast specific protein 1 and transforming growth factor β expressions were also significantly decreased by bilirubin treatment (p<0.001). In addition, expressions of hypoxia-inducible factor 1 α and vascular endothelial growth factor were up-regulated significantly (p<0.01).

Conclusion: Bilirubin treatment could improve kidney fibrosis by regulation of hypoxia-inducible factor 1 α pathway.

Key Words: 빌리루빈, 신섬유화, HIF1 α

Bilirubin, Kidney fibrosis, HIF1 α